Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
Rani Therapeutics (RANI) had its price target lowered by Canaccord Genuity Group Inc. from $9.00 to $5.00. They now have a "buy" rating on the stock.
Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth [Yahoo! Finance]
Rani Therapeutics (RANI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript [Seeking Alpha]